Advances in Ion Channel Drug Discovery

Approximately 13% of approved drugs have mechanisms involving the modulation of ion channel activity, which makes ion channels the second-largest mechanistic class of marketed compounds. Currently approved drugs address important disease areas including diabetes, epilepsy, hypertension, cardiac arrhythmia, anxiety, and pain.

Approximately 35% of agents in development have big pharma sponsorship, with the remaining 65% under development by smaller biotech. CNS indications account for 45% of development programs. Agents in late-stage development include several first-in-class agents acting at the cystic fibrosis transmembrane regulator, and new NMDA and AMPA antagonists.

Earlier-stage programs focus on selective Nav blockers (following on from genetic validation of Nav1.7 involvement in pain), subtype-selective NMDA and AMPA blockers, and a large number of TRP family members for a variety of indications.

Features and benefits
• Understand the competitive landscape in ion channel modulation and compare the pipelines of specialist companies operating in this area
• Identify the most promising targets from a "likelihood of success" viewpoint.
• Identify the targets with scope for ion channel intervention and major market opportunity.
• Understand which advances in target discovery, technology, and clinical development will have biggest impact to move the area forward.
• Benchmark available technologies against the gold standard for ion channel discovery.

Ion Channel Drug Discovery

Published: March 2012
No. of Pages: 194
Price: Single User License – US$3835             Corporate User License – US$14381





 

Your key questions answered
• Why have ion channels been underexploited and what is changing to enable greater realization of these targets' potential?
• What disease areas offer further scope for new ion channel modulators, and which are likely to have the best market potential?
• Which companies have the most promising late development candidates?
• Which companies are offering innovative technologies to facilitate the discovery of drugs acting at ion channel targets?
• What challenges remain to be overcome in fully exploiting the possibilities presented by modulation of ion channel targets?

Major points covered in Table of Contents of this report include:
EXECUTIVE SUMMARY
Introduction
Characteristics of ion channels
Commercial exploitation
Discovery approaches
New opportunities
Specialist company profiles
Outlook
Appendix
List of Tables
List of Figures                                                  

Browse reports related to Pharmaceuticals @ http://www.reportsnreports.com/market-research/pharmaceuticals/

Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction

This report provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in the US with key data, information and analysis of pricing and reimbursement decisions across the US. The report closely scrutinizes major changes in pharmaceuticals-related pricing and reimbursement in the US in the recent past and the impact these changes will have in the future. It also describes the efforts taken by the US government and private sector in shaping the pricing and reimbursement policies of brand name and generic drugs. The pricing and reimbursement scenario in some of the major therapy areas of the US has been described with the help of informative case studies.

Scope
• Detailed study of the healthcare systems in the US.
• Political, economical, social and technological analysis of the US pharmaceutical industry.
• Analysis of the pricing and reimbursement mechanisms in the US.
• Key trends that follow from the recent changes brought about in the pricing and reimbursement system.
• Build an understanding of the possible major challenges that may arise due to the changes in the pricing and reimbursement scene in the US.
• Insight into various reimbursement programs in the US with case studies.
• Particular focus on the pricing and reimbursement in major therapy areas with case studies.

Pricing and Reimbursement in US Pharmaceuticals Market

Published: February 2012

No. of Pages: 75

Price: Single User License – US$3500    Corporate User License – US$10500 

                                        
Reasons to buy
• Build an understanding of the pharmaceuticals-related key pricing and reimbursement mechanisms in the US.
• Optimize your investment through identification and understanding of the changes in the pharmaceuticals regulatory mechanism in the US.
• Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in the pricing and reimbursement scene of the US.
• Improve negotiations with the government agencies to maximize reimbursement of drugs by understanding the mechanisms involved.

Explore Comprehensive list of Tables & Figures available in the report @ http://www.reportsnreports.com/reports/145418-pricing-and-reimbursement-in-the-us-non-lis-beneficiaries-not-covered-by-medicare-coverage-gap-to-gain-from-reduction-in-out-of-pocket-expenditure-for-generic-drugs.html.

Epidemiology: Migraine – Stable adult population under 50 years will result in stable migraine prevalence

Migraine mainly affects adults aged between 18 and 49 years. Datamonitor expects a relatively stable number of migraine cases through to 2020 in the seven major markets as a result of a stable adult population.

Migraine has a high burden, as it affects productive adults and requires long-term treatment. Stroke, epilepsy, sinus headache, and psychiatric disorders are the main co-morbidities associated with migraine.

Request a Sample for or Inquire before buying the report @ http://www.reportsnreports.com/reports/144337-epidemiology-migraine-stable-adult-population-under-50-years-will-result-in-stable-migraine-prevalence.html

In this analysis, Datamonitor estimates that there were a total of 67.3 million cases of migraine in 2010 in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK). Prevalence rates for migraine are expected to remain constant as it is primarily a hereditary condition that can also be affected by hormonal changes, stress, and depression.

Features and benefits
• Gain insight into market potential, including a robust 10-year epidemiology forecast of prevalent migraine cases.
• Understand the key epidemiologic risk factors associated with migraine.

Explore Tables of Contents available in the report Epidemiology: Migraine – Stable adult population under 50 years will result in stable migraine prevalence.

Mitsubishi Tanabe Pharma Corp.: PharmaVitae Profile

Datamonitor has identified 10 launch products in Mitsubishi Tanabe’s product portfolio, which are expected to provide $802m in sales growth out to 2016.

Features and benefits
• Gain insight into Mitsubishi Tanabe's strategic outlook across the next 6 years
• Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Request a Sample for or Inquire before buying the report @
http://www.reportsnreports.com/reports/83958-mitsubishi-tanabe-pharma-corp-pharmavitae-profile.html

This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

 Major points covered in Table of Contents of this report include:
• EXECUTIVE SUMMARY
• STRATEGIC INSIGHT
• COMPANY INTRODUCTION
• SALES ANALYSIS
• PRODUCT ANALYSIS
• APPENDIX
• Tables and Figures

Explore Table of Contents available in the report Mitsubishi Tanabe Pharma Corp.: PharmaVitae Profile.

Orphan Drug Trends 2011

Orphan Drug Trends 2011 - With the industry’s ongoing transition toward more niche high-value therapies, a growing number of companies are expanding into the orphan drugs arena, fuelled by the incentives offered by national regulatory authorities, the high price point orphan drugs can achieve, and the limited competition they face.

Features and benefits

An overview of orphan drug designation policies in the major pharmaceutical markets
Insight into pricing and reimbursement challenges faced by orphan drug manufacturers
Review of Orphan Drug Market R&D, designation, and approval trends in the US market
Orphan drug deal trend and case study analysis

Highlights
• With the growing number of orphan drugs entering the market, products are facing tougher scrutiny from payers, with pricing and reimbursement remaining the most significant hurdle to market access, leading to the use of risk-sharing agreements by a number of manufacturers.
• Pharma’s shift toward niche markets is occurring either by gradually undertaking several bolt-on deals with specialist players, as exemplified by GlaxoSmithKline and Pfizer, or opting for a large scale merger or acquisition to rapidly access the target company’s orphan drug portfolio, as illustrated by Sanofi’s purchase of Genzyme.
• The majority of orphan drug candidates targeted by pharma are in Phase III clinical trials, and are accessed primarily through licensing deals. Nevertheless, pharma is also keen to access orphan drugs during pre-clinical development. Often these deals involve smaller up-front fees, with greater emphasis on commercial milestone and royalty payments.

The World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition (Pre-Publication)

Published: October2011
No. of Pages: 245
Price: $ 2995

This Kalorama Information report - The World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition - focuses on several segments for cancer treatment including:

• Chemotherapy, including -subcategories Alkylating Agents, Antimetabolites, Cytotoxic Agents, Plant Derivatives -Brands such as Elotaxin, Taxotere, Gemzar, Alimta and Temodar with Market Share for each

• Hormone Therapy: -Subcategories include Corticosteroids, Hormone Agonists/Antagonists, Aromatase Inhibitors and SERMS-Brands such as Arimidex, Casodex, Zoladex, Femara and Lupron with Market Share for each.

• Immunotherapy and Biotherapy, including: -Monoclonal antibodies, interleukins/interferons, vaccines and other biotherapy-Brands such as Rituxan, Herceptin, Gleevec, Evastin and Erbitux

One of the most promising new approaches in modern cancer treatment is immunotherapy or biotherapy, the development of methods to augment and enhance the body’s natural tendency to defend itself against malignant tumors without damaging healthy tissue. The report devotes particular attention to these new therapies.

Browse All: Pharmaceuticals Market Research Reports

This report, Kalorama's fourth complete research effort into the oncology treatments market in the past ten years, provides market size information for the various types of cancers including the following:

• Bladder

• Breast

• Cervical

• Colorectal

• Esophageal

• Head/Neck

• Kidney

• Leukemia

• Liver

• Lung

• Lymphoma

• Melanoma

• Multiple Myeloma

• Neuroblastoma

• Ovarian

• Pancreatic

• Prostate

• Stomach

The report covers both currently marketed and late stage development cancer products. Revenues for each current market segment were generated using dollar and unit sales for each product.

The report includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development and/or have significant incidence/mortality rates are profiled. The market segments provide an overview, description of products on the market, leading product sales, market estimates and forecasts, and competitive analysis of leading providers. The report also includes a list of products in development and current issues and trends affecting the industry.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

As part of its coverage, the report looks at the following trends

• Insurance and Reimbursement Issues

• Cancer Drug Costs

• Personalized Medicine

• Targeted Cancer Therapy

• Pharmacogenomics

• Alliances Acquisitions and Licensing Agreements

• Patient-Reported Outcomes

• Alcohol’s Affect on Cancer Incidence

• Healthy Lifestyles Continue to Show Promise for Cancer Prevention

• Obesity in the U.S.

• Outlook for a Healthier U.S. Population

• Cancer Trends

• Marketing and Distribution Trends

• Geographical Trends (US, Europe, Japan)

• Elderly Clinical Trial Involvement

• Late-Stage Drug Development Trends

All market data pertains to the world market at the manufacturers’ level. The base year for data was 2010. Historical data was provided for the years 2005 through 2009, with forecast data provided for 2011 through 2015. Compound annual growth rates (CAGRs) are provided for the 2005-2010, 2010-2015 and 2005-2015 periods for each industry segment covered. Competitive analysis is provided for the year 2010. The forecasted market analysis for 2010-2015 was based on probability of approval and sales of products in late stage development, competitive trends, product marketing, and demographic trends.